“…Twenty peer-reviewed articles were reviewed from 1997 to 2013 [4,8,12,14,15,16,22,23,24,25,26,27,28,29,30,31,32,33,34,35]. All patients treated with radiation therapy only were recorded.…”
Section: Resultsmentioning
confidence: 99%
“…As EMZL is an indolent form of lymphoma, radiotherapy has long been the treatment of choice for localized disease [14,15,16]. Long-term survival and excellent local control have been documented with radiotherapy alone [4,9,10,14,15].…”
Section: Introductionmentioning
confidence: 99%
“…Long-term survival and excellent local control have been documented with radiotherapy alone [4,9,10,14,15]. It is estimated that using low to moderate radiotherapy doses (25-36 Gy) can obtain 95-100% of local control [4,11,17].…”
Aim: The aim of this study was to report outcomes following radiation therapy in patients with biopsy-proven extranodal marginal zone lymphoma of the ocular adnexa and uvea. Methods: Records from a single institution were retrospectively reviewed from January 1997 to December 2015. The mean follow-up duration was 38 months (range 0-194). Radiation therapy was administered to 77 eyes (60 patients); 57 of the 77 eyes (74%) were treated with radiation only (range 20-36 Gy, median 15 fractions). Radiation cataract, radiation retinopathy, and optic neuropathy assessments were performed on all eyes treated with radiation. Results: 100% of the 47 patients treated with radiation therapy only had local control with an average dose of 26.5 Gy (median 25.2 [range 20-36] Gy; 150-200 cGy per fraction). Four patients lost 2 lines or more of vision after radiation. The most common complication of radiation therapy was cataract formation/progression in 19 eyes (25%). Radiation retinopathy was observed only in 1 patient (1%). Conclusion: Our results confirm that radiation therapy (median 25 Gy) for extranodal marginal zone lymphoma of the ocular adnexa is associated with high local control and low risk of visually significant complications.
“…Twenty peer-reviewed articles were reviewed from 1997 to 2013 [4,8,12,14,15,16,22,23,24,25,26,27,28,29,30,31,32,33,34,35]. All patients treated with radiation therapy only were recorded.…”
Section: Resultsmentioning
confidence: 99%
“…As EMZL is an indolent form of lymphoma, radiotherapy has long been the treatment of choice for localized disease [14,15,16]. Long-term survival and excellent local control have been documented with radiotherapy alone [4,9,10,14,15].…”
Section: Introductionmentioning
confidence: 99%
“…Long-term survival and excellent local control have been documented with radiotherapy alone [4,9,10,14,15]. It is estimated that using low to moderate radiotherapy doses (25-36 Gy) can obtain 95-100% of local control [4,11,17].…”
Aim: The aim of this study was to report outcomes following radiation therapy in patients with biopsy-proven extranodal marginal zone lymphoma of the ocular adnexa and uvea. Methods: Records from a single institution were retrospectively reviewed from January 1997 to December 2015. The mean follow-up duration was 38 months (range 0-194). Radiation therapy was administered to 77 eyes (60 patients); 57 of the 77 eyes (74%) were treated with radiation only (range 20-36 Gy, median 15 fractions). Radiation cataract, radiation retinopathy, and optic neuropathy assessments were performed on all eyes treated with radiation. Results: 100% of the 47 patients treated with radiation therapy only had local control with an average dose of 26.5 Gy (median 25.2 [range 20-36] Gy; 150-200 cGy per fraction). Four patients lost 2 lines or more of vision after radiation. The most common complication of radiation therapy was cataract formation/progression in 19 eyes (25%). Radiation retinopathy was observed only in 1 patient (1%). Conclusion: Our results confirm that radiation therapy (median 25 Gy) for extranodal marginal zone lymphoma of the ocular adnexa is associated with high local control and low risk of visually significant complications.
“…For ocular tumors, the first choice of treatment for MALT lymphoma is radiotherapy, which is associated with a good prognosis, with a 5-year survival rate of 97.6 % and a 10-year survival rate of 93.5 %. Chemotherapy is usually administered in the event of disease recurrence [18].…”
The patient was a 74-year-old Japanese woman with rheumatoid arthritis (RA) who developed generalized lymphadenopathy with elevated levels of lactase dehydrogenase (LD), and soluble IL-2 receptor (sIL-2R). She was found to be positive for anti-human T-cell leukemia virus type 1 (HTLV-1) antibodies. Her symptoms and laboratory abnormalities spontaneously regressed after the cessation of methotrexate (MTX), suggesting that she had an MTX-associated lymphoproliferative disorder; however, her lymphadenopathy appeared again approximately 14 months later with LD and sIL-2R elevation. A histopathological analysis and Southern blotting of a lymph node biopsy specimen for HTLV-1 provirus supported the diagnosis of adult T-cell leukemia/lymphoma (ATL) (lymphoma type). These data confirmed that an HTLV-1 positive RA patient may develop ATL.
“…2 More than half of the OALs are extranodal marginal zone B cell lymphomas of mucosa-associated lymphoid tissue lymphomas (MALT). 3 Less common B cell lymphoma subtypes include follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), plasmacytoma, lymphoplasmacytic lymphoma, mantle cell lymphoma (MCL), and even hairy cell leukemia. 1,4,5 Because of distinctive epidemiologic patterns in different geographic areas as well as different environmental and genetic factors, several microbiologic agents, especially Chlamydophila psittaci, have been considered to play a role in the etiology of OAL.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.